SLC5A2 and cardiovascular disorder: In summary, SGLT2 inhibitors reduce MACE in patients with known atherosclerotic cardiovascular disease, cardiovascular risk factors including hypertension, dyslipidaemia, overweight/obesity, and have a profound effect on preventing hospitalisation for heart failure, as well as reducing the risk of worsening estimated glomerular filtration rate, end-stage kidney disease, or renal death.